Recombinant multi-species AKR1C1 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine AKR1C1 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene encodes a member of the aldo/keto reductase superfamily, which consists of more than 40 known enzymes and proteins. These enzymes catalyze the conversion of aldehydes and ketones to their corresponding alcohols by utilizing NADH and/or NADPH as cofactors. The enzymes display overlapping but distinct substrate specificity. This enzyme catalyzes the reaction of progesterone to the inactive form 20-alpha-hydroxy-progesterone. This gene shares high sequence identity with three other gene members and is clustered with those three genes at chromosome 10p15-p14. [provided by RefSeq, Jul 2008]
The Alternative Names of target: 2-ALPHA-HSD,20-ALPHA-HSD,20-alpha-hydroxysteroid dehydrogenase (20-alpha-HSD),AKR1C1,Aldo-keto reductase family 1 member C1,C9,Chlordecone reductase homolog HAKRC,DD1,DD1/DD2,DDH,DDH1,Dihydrodiol dehydrogenase 1 (DD1),H-37,HAKRC,HBAB,High-affinity hepatic bile acid-binding protein (HBAB),MBAB

Target products collectionGo to AKR1C1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-IP6105-Ag-1/ GM-Tg-hg-IP6105-Ag-2 Human AKR1C1 protein Human
GM-Tg-rg-IP6105-Ag-1/ GM-Tg-rg-IP6105-Ag-2 Rat AKR1C1 protein Rat
GM-Tg-mg-IP6105-Ag-1/ GM-Tg-mg-IP6105-Ag-2 Mouse AKR1C1 protein Mouse
GM-Tg-cynog-IP6105-Ag-1/ GM-Tg-cynog-IP6105-Ag-2 Cynomolgus/Rhesus macaque AKR1C1 protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-IP6105-Ag-1/ GM-Tg-felg-IP6105-Ag-2 Feline AKR1C1 protein Feline
GM-Tg-cang-IP6105-Ag-1/ GM-Tg-cang-IP6105-Ag-2 Canine AKR1C1 protein Canine
GM-Tg-bovg-IP6105-Ag-1/ GM-Tg-bovg-IP6105-Ag-2 Bovine AKR1C1 protein Bovine
GM-Tg-equg-IP6105-Ag-1/ GM-Tg-equg-IP6105-Ag-2 Equine AKR1C1 protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-IP6105-Ag-1/ GM-Tg-hg-IP6105-Ag-2; GM-Tg-rg-IP6105-Ag-1/ GM-Tg-rg-IP6105-Ag-2;
GM-Tg-mg-IP6105-Ag-1/ GM-Tg-mg-IP6105-Ag-2; GM-Tg-cynog-IP6105-Ag-1/ GM-Tg-cynog-IP6105-Ag-2;
GM-Tg-felg-IP6105-Ag-1/ GM-Tg-felg-IP6105-Ag-2; GM-Tg-cang-IP6105-Ag-1/ GM-Tg-cang-IP6105-Ag-2;
GM-Tg-bovg-IP6105-Ag-1/ GM-Tg-bovg-IP6105-Ag-2; GM-Tg-equg-IP6105-Ag-1/ GM-Tg-equg-IP6105-Ag-2
Products Name AKR1C1 protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name AKR1C1
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine AKR1C1 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.